Principles of assessment of abuse liability: US legal framework and regulatory environment

Behavioural Pharmacology

Volumn 24, Issue 5-6, 2013, Pages 403-409

  Rocha, Beatriz A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

abuse liability; abuse potential; controlled substances regulation; drug abuse control

Indexed keywords

ANABOLIC AGENT; CENTRAL STIMULANT AGENT; CONTROLLED SUBSTANCE; ILLICIT DRUG; LORCASERIN; NARCOTIC AGENT; PRESCRIPTION DRUG; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT;

DRUG ABUSE; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; INFORMATION PROCESSING; LEGAL LIABILITY; MEDICAL ASSESSMENT; NATIONAL HEALTH ORGANIZATION; POSTMARKETING SURVEILLANCE; REVIEW; UNITED STATES;

ANIMALS; CONTROLLED SUBSTANCES; DRUG AND NARCOTIC CONTROL; HUMANS; RISK ASSESSMENT; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84881544879     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328363d163     Document Type: Review

References (27)

1. Balster RL, Bigelow GE (2003). Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70:S13-S40
2. Barkan ID (1985). Industry invites regulation: The passage of the Pure Food and Drug Act of 1906. Am J Public Health 75:18-26
3. Bureau of Justice Statistics (1992). Drugs, crime and the justice system: A national report from the Bureau of Justice Statistics. Washington, DC: US Department of Justice, Office of Justice ProgramsAvailable at: Http:// www.bjs.gov/index.cfm?ty = pbdetail&iid = 4071. pp. 76-80
4. Code of Federal Regulations (CFR). Title 21 Part 314.50(d)(5)(vii). Application for FDA to market a new drug; content and format of an application; clinical data section
5. European Medicines Agency (EMA)/Committee For Medical Products for Human Use (CHMP) (2006). Guideline of the non-clinical investigation on the dependence potential of medicinal products. EMA/CHMP/SWP/94227/2004. London, UK: European Medicines Agency 2006; Available at: Http:// www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/ 2009/09/WC500003360.pdf
6. Food and Drug Administration (FDA), Extended Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) (2012). Available at: Http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ UCM311290.pdf [Accessed 13 June 2013
7. Federal Register (2012). Federal Register/Vol. 77, No. 244/19 December 2012/ Proposed Rules-[Docket No. DEA-369]. Schedules of controlled substances: Placement of lorcaserin into schedule IV.
8. Food and Drug Administration (FDA)/Center for Drug Evaluation and Research (CDER) (2010). Draft guidance for industry: Assessment of abuse potential of drugs. Silver Spring, MD: US Department of Health and Human Service 2010; Available at: Http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM198650.pdf
9. Food and Drug Administration Safety and Innovation Act (FDASIA) (2012). Available at: Http://www.fda.gov/RegulatoryInformation/Legislation/Federal FoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ FDASIA/default.htm [Accessed 13 June 2013
10. Food and Drug Administration (FDA)/Center for Drug Evaluation and Research (CDER) (2013). Draft guidance for industry: Abuse-Deterrent opioids-evaluation and labeling. Silver Spring, MD: FDA/CDER 2013; Available at: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryn formation/Guidances/UCM334743.pdf
11. Food and Drug Administration (FDA) Voice (2013). Available at: Http:// blogs.fda.gov/fdavoice/index.php/2013/04/the-science-of-Abuse- Deterrenceprogress-Toward-creating-safer-opioids/ [Accessed 13 June 2013
12. Harrison Narcotics Tax Act (1914). Public Acts of the Sixty-Third Congress of the United States. Available at: Http://www.naabt.org/documents/ Harrison- Narcotics-Tax-Act-1914.pdf; http://www.druglibrary.org/schaffer/ history/e1910/ harrisonact.htm [Accessed 13 June 2013
13. Health Canada (2007). Clinical assessment of abuse liability for drugs with central nervous system activity. Ottawa, Ontario: Health Canada 2007; Available at: Http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-Demande/ guide-Ld/abus/abuse-liability-abusif-usage-clin-eng.php
14. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use-ICH Harmonized Tripartite Guideline: Safety Pharmacology Studies For Human Pharmaceuticals S7A (2000). Available at: Http://www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Safety/S7A/Step4/S7A-Guideline.pdf [Accessed 13 June 2013
15. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use-ICH Harmonized Tripartite Guideline: Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3 (R2) (2009). Available at: Http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/ Multidisciplinary/M3-R2/Step4/M3-R2--Guideline.pdf [Accessed 13 June 2013
16. Memorandum of Understanding (MOU) 225-85-8251 (1985). The National Institute on Drug Abuse (PHS/HHS) concerning cooperative interaction in expediting domestic scheduling of drugs of abuse. Available at: Http://www. fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstanding MOUs/DomesticMOUs/ucm116365.htm [Accessed 13 June 2013
17. National Institute on Drug Abuse (NIDA) and Food and Drug Administration (FDA) (2011). Science of abuse liability assessment. Bethesda, Maryland: NIDA and FDA 2011; Available at: Http://www.seiservices.com/nida/ 1014102/agenda.aspx
18. Parker JM (2006). Overview of drug control: A regulatory primer on scheduling and controlled substance regulations. Clin Res Regul Aff 23:211-225
19. PhRMA-FDA Dialogue Session (2008). Abuse potential assessment. Available at: Http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedical ProductsandTobacco/CDER/UCM180769.pdf [Accessed 13 June 2013
20. Pure Food and Drug Act (1906). Alcohol, morphine, opium, cocaine, heroin, alpha or beta eucaine, chloroform, Cannabis indica, chloral hydrate, acetanilide or any derivative or preparation thereof. United States Statutes at Large (59th Cong., Sess. I, Chapter 3915, pp. 768-772; cited as 34 US Stats. 768
21. Rocha BA, Bergman J, Comer SD, Haney M, Spealman RD (2008). Chapter 7: Development of medications for heroin and cocaine addiction and regulatory aspects of abuse liability testing. In: MacArthur RA, Borsini F, editors. Animal and translational models for CNS drug discovery. Vol. 3: Burlington, MA: Academic Press, an imprint of Elsevierpp. 223-270
22. Rocha BA, Martynowicz H, Usher RW, Friedman A, Parker J, Fanelli R, et al. (2011). Companies unite to advance regulatory landscape of abuse potential assessment. Regul Focus 16:8-13
23. Title 21 United States Code (USC) Controlled Substances Act, Section 801 (21USC801), congressional findings and declarations: Controlled substances. Available at: Http://www.deadiversion.usdoj.gov/21cfr/21usc/ 801.htm [Accessed 13 June 2013
24. Title 21 United States Code (USC) Controlled Substances Act, Section 802 (21USC802)-Definitions. Available at: Http://www.deadiversion.usdoj.gov/ 21cfr/21usc/802.htm [Accessed 13 June 2013
25. USC (2012a). Title 21 United States Code (USC) Controlled Substances Act, Section 812 (21USC812)-Schedules of controlled substances. Available at: Http://www.deadiversion.usdoj.gov/21cfr/21usc/812.htm [Accessed 13 June 2013
26. World Health Organization United Nations Single Convention on Narcotic Drugs (1961). Available at: Http://www.unodc.org/unodc/en/treaties/single- convention. html?ref =menuside
27. World Health Organization United Nations Convention on Psychotropic Substances (1971). Available at: Http://www.unodc.org/pdf/convention- 1971-en.pdf